Coulter Partners recruits two to Curetis NV Supervisory Board
Posted: 3 November 2015 |
Coulter Partners was delighted to partner with German diagnostics company Curetis AG on two strategic supervisory board appointments and congratulates them on their recent IPO launch…
“I truly enjoyed working with you and the entire Coulter Partners team – one of the best search firm experiences I have ever had in the healthcare space over the past 17 years.” Oliver Schacht, PhD, CEO, Curetis AG
Coulter Partners was delighted to partner with German diagnostics company Curetis AG on two strategic supervisory board appointments and congratulates them on their recent IPO launch. Tasked with finding a Chairman of the Board and a Chair of the Audit Committee, our trans-Atlantic team needed to identify candidates with a background in diagnostics and capital markets, who had experience with European business cultures. With Curetis’ public offering imminent, we were able to develop models that attracted US-based candidates as well as European candidates with significant US experience, and the search was successfully concluded. Curetis have appointed two seasoned executives with experience in public offerings, diagnostics, German and US markets, and with prior directorships.
The full announcement from Curetis follows:
Curetis Announces New Supervisory Board of Curetis N.V.
Curetis B.V.1 (“Curetis”), a developer of next-level molecular diagnostic solutions, announced the composition of its supervisory board. William E. Rhodes, III, will be serving as chairman of Curetis’ supervisory board (the “Board”), while Mario Crovetto will serve as chairman of Curetis’ audit committee. Board members Dr. Werner Schaefer, Dr. Frank Muehlenbeck, Dr. Rudy Dekeyser, and Dr. Holger Reithinger have previously been members of the supervisory board of Curetis AG.
William Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry, and has been serving as an Operating Partner with Linden Capital Partners´ investment team since January 2013. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012), Mr. Rhodes was an Executive Officer and held several senior leadership positions, including roles as Worldwide President of BD Biosciences (2009-2011). He was responsible for BD’s corporate M&A activities as well as leading and growing operating companies. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he held senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also has served, among other roles, as President of The William-James Co. and has a track record of more than 20 successful acquisitions and divestitures. Mr. Rhodes holds a Master’s degree in International Business from Seton Hall University and a BSc degree from Cornell University.
Mario Crovetto has been working as an independent advisor on M&A and corporate projects, notably integrations, divestments and financing since 2011. From 1999 to 2011, he was the CFO of Eurand NV (Specialty Pharmaceuticals), which he took public on NASDAQ in 2007. From 1990 to 1999, he held various senior business positions at Recordati (Pharma-ceuticals), including VP of Corporate Development, Division Manager of Diagnostics and CFO. Prior to that, he worked in various positions at Montedison (Speciality Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting). Mr. Crovetto holds a BSc in Economics from the Università Cattolica del Sacro Cuore, Milan, and a Master’s degree in Business Economics from Harvard University, Cambridge, MA.
“We are very happy to have won two leading, seasoned experts with tremendous experience in the diagnostics industry and capital markets for our Board,” said Oliver Schacht, PhD, CEO of Curetis. “Both bring long-standing expertise in business development in the diagnostics and the pharma industry.”
“It is a great pleasure for me to join the Board of Curetis,” said William Rhodes, Operating Partner with Linden Capital Partners. “Experts all over the world agree that fast, early and reliable diagnosis of pathogens and antibiotic resistance is key for better antibiotic stewardship, and Curetis has developed a very innovative approach to provide a solution for this pressing problem.”
1 Curetis B.V. will be converted into Curetis N.V.
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.